Condition
Chemotherapy Induced Systolic Dysfunction
Total Trials
6
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Unknown4
Recruiting1
Not Yet Recruiting1
Clinical Trials (6)
Showing 6 of 6 trials
NCT05756608Recruiting
Fibrosis in Chronic and Delayed Myocardial Infarction
NCT06304896Phase 1Not Yet RecruitingPrimary
Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy
NCT05992337Unknown
New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
NCT04510532Unknown
Early Detection of CMP in Patients With Breast Cancer Using Cardiac Magnetic Resonance
NCT04461223Unknown
Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR
NCT04046315Unknown
Early Detection of Cardiac Damage With CMR in Women With Breast Cancer
Showing all 6 trials